Clinical Trials

The purpose of this study is to develop an artificial intelligence (AI) system than can process MR images acquired using conventional acquisition schemes (spin echo, gradient echo, etc) and contrasts (T1, T2, T2*, PD) to identify the MR fingerprint of the tissue under interrogation.

The purpose of this study is to prospectively clarify the long-term consequences of SARS-CoV-2 infection in the CNS with multi-modal magnetic resonance (MR) imaging tracking structural, microstructural, vascular and biochemical changes.

COVID-19 increases the risk of developing long-term inflammatory, neurodegenerative and cerebrovascular consequences.

VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, and explore these biomarkers in acute intracerebral hemorrhage. VERIFY will create the first multicenter, large-scale, prospective dataset of clinical, transmagnetic stimulation (TMS), and MRI measures in the acute stroke time window.

To better understand the effects of positional brain shift in normal healthy individuals, specifically between the cortical surface and dura. To identify and characterize these regions of interest.

The purpose of this study is to evaluate the safety and effectiveness of using Exablate Model 4000 Type-2.0/2.1 in adults with Glioblastoma brain tumors to increase temporarily the permeability of the blood brain barrier, allowing increased passage of circulating free DNA (cfDNA) for sampling and analysis.